We were delighted to have the opportunity to speak with Expert Faculty member Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) about the biology of the IL-23 pathway in psoriasis and the therapeutic use of IL-23 inhibitors.
- Could you give us a brief overview of the role of the IL-23 in the pathogenesis of psoriasis? (1:46)
- What clinical evidence supports the use of selective IL-23 inhibitors in the treatment of psoriasis? (2:50)
- What are the main safety risks associated with IL‐23 inhibitors in patients with psoriasis? (3:56)
- How is the role of IL-23 inhibitors likely to evolve in the future? (4:28)
Disclosures: Tiago Torres has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the 29th EADV Virtual Congress 2020.
Share this Video
Related Videos In Psoriasis
Diamant Thaçi, EADV 2020: Long-term Efficacy of Tildrakizumab in Psoriasis
It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754). Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled […]
Lluís Puig, EADV 2020 – New Therapeutic Targets in Psoriasis
We were delighted to be able to speak with Lluís Puig (Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain) about novel pathophysiology-based therapeutic agents in the treatment of psoriasis. His full presentation entitled ‘New therapeutic targets based on pathophysiology’ was presented at the EADV Virtual Congress 2020. Questions Could you give us a brief […]
Kim Papp, EADV 2020 – Sonelokinab for Chronic Plaque Psoriasis
We were delighted to discuss with Kim Papp (Probity Medical Research, Waterloo, ON, Canada) the results of the phase IIb study assessing the efficacy, safety and tolerability of sonelokinab (M1095), and IL-17 A/F nanobody, in patients with moderate-to-severe chronic plaques psoriasis (Clinical Trial Identifier: NCT03384745) Questions What are the major unmet needs in the treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!